News

Risk lower for HF, but not major CV events, compared with new users of DPP4 inhibitors

At normal body weight, rates for diabetes three times higher in Hawaiians, Pacific Islanders

Linagliptin compared with glimepiride for risk for major cardiovascular events in T2DM with elevated CV risk

Risk for major adverse cardiovascular events reduced with metformin compared with a sulfonylurea

Findings based on survey of university-affiliated students, staff with either type 1 or type 2 diabetes

Primary care doctors have limited knowledge about screening, management for prediabetes

Incidence rising in 33 percent of populations versus increase in 66 percent of populations in 1990 to 2005

Highest rates reported among preschoolers, children, and adolescents aged younger than 15 years

Correlation attenuated after adjustment for liver fat and triacylglycerols, adiponectin, CRP

Retrospective analysis of adverse events reported to FDA shows risk similar to that seen with methadone